



OPEN ACCESS

EDITED AND REVIEWED BY
Baohui Xu,
Stanford University, United States

*CORRESPONDENCE
Yiguang Lin
Yiguang.lin@hotmail.com
Feng Xu
13840157712@163.com

SPECIALTY SECTION
This article was submitted to
Cardiovascular Therapeutics,
a section of the journal
Frontiers in Cardiovascular Medicine

RECEIVED 21 October 2022
ACCEPTED 07 November 2022
PUBLISHED 05 December 2022

CITATION
Chen H, Chen J, Zhang F, Li Y, Wang R,
Zheng Q, Zhang X, Zeng J, Xu F and
Lin Y (2022) Corrigendum: Effective
management of atherosclerosis
progress and hyperlipidemia with
nattokinase: A clinical study with 1,062
participants.
Front. Cardiovasc. Med. 9:1076420.
doi: 10.3389/fcvm.2022.1076420

COPYRIGHT
© 2022 Chen, Chen, Zhang, Li, Wang,
Zheng, Zhang, Zeng, Xu and Lin. This is
an open-access article distributed
under the terms of the [Creative
Commons Attribution License \(CC BY\)](#).
The use, distribution or reproduction
in other forums is permitted, provided
the original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which
does not comply with these terms.

Corrigendum: Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants

Hongjie Chen¹, Jiepeng Chen², Fuping Zhang³, Yuanhui Li⁴,
Ronghua Wang², Qiang Zheng², Xu Zhang², Jun Zeng²,
Feng Xu^{5*} and Yiguang Lin^{1,6,7*}

¹Department of Traditional Chinese Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²Sungen Bioscience Co. Ltd., Shantou, China, ³Department of Pharmacy, Shenyang Red Cross Hospital, Shenyang, China, ⁴Guangzhou Center, Sinopharm Group Pharmaceutical Co., Ltd., Guangzhou, China, ⁵Antithrombotic & Thrombolytic Innovative Drug Research Center, Shenyang Pharmaceutical University, Shenyang, China, ⁶The Central Laboratory, First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China, ⁷School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia

KEYWORDS

nattokinase, atherosclerosis, hyperlipidaemia, anti-atherogenic drug, lipid lowering effect, retrospective study, lipid lowering agent, Nattokinase (NK)

A corrigendum on

Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants

by Chen, H., Chen, J., Zhang, F., Li, Y., Wang, R., Zheng, Q., Zhang, X., Zeng, J., Xu, F., and Lin, Y. (2022). *Front. Cardiovasc. Med.* 9:964977. doi: 10.3389/fcvm.2022.964977

In the published article, there was an error in **Table 1** Baseline characteristics of the participants as published.

The corrected Table and correct format appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 1 Baseline characteristics of the participants.

Age (year)	67.5 (63–85)
Gender	
Male	491
Female	571
Exercise	
<5,000 steps/d	356
>5,000 steps/d	706
BMI	
<27.5	980
>27.5	82
Smoker	259
Alcohol drinking	
<100 ml/w	799
>100 ml/w	263
Vitamin K2 co-admin (180 µg/d)	181
Aspirin co-admin (100 mg/d)	96
Hyperlipidemia	1,062
Atherosclerosis	683
